1. Dual kinase inhibitor for EGFR mutants and ErbB2 limit breast cancer.
- Author
-
Goel, Peeyush N., Zhang, Hongtao, Murali, Ramachandran, Zheng, Cai, Ji, Mei Q., Patterson, Angelica, Grover, Payal, and Greene, Mark
- Subjects
- *
KINASE inhibitors , *PROTEIN-tyrosine kinases , *NON-small-cell lung carcinoma , *PROTEIN-tyrosine kinase inhibitors , *BREAST cancer , *EPIDERMAL growth factor receptors - Abstract
Mutations in the epidermal growth factor receptor (EGFR) have been found in more than 10% of non-small cell lung cancer (NSCLC) patients in North America. The vast majority of these differences are L858R point mutations in Exon 21. Currently, monoclonal antibodies directed against the extracellular domain of EGFR or small molecule/tyrosine kinase inhibitors (TKI) are the stalwarts of NSCLC therapy. Resistance, however, gradually develops because of the T790 mutation towards first and second generation TKIs. The third generation TKI AZD9291 (Osimertinib) has a high affinity for both activating and the acquired resistant mutation (T790 M) in EGFR, with a low affinity towards wild-type EGFR. Recent research, however, suggests that the EGFR (C797S) mutation in the tyrosine kinase domain is a likely cause of resistance to AZD9291. Another significant transformation mechanism associated with this resistance is erbB2 amplification. Our laboratory has developed a small kinase inhibitor, ER121 (MW: ∼500), that inhibits the erbB2/HER2 tyrosine kinases in addition to the EGFR C797S mutations. We have identified a TKI, ER121 targeting the mutant EGFR(T790 M). Using in vitro and in vivo models, examined the efficacy of ER121 on mutant EGFR cell lines. This has enabled us to establish that ER121 is well tolerated when administered orally and produces significant inhibitory activity against human cancers generated by mutant EGFR and amplified ErbB2. • ER121, a dual kinase inhibitor targets both mutant EGFR and activated erbB2. • ER121 inhibits EGFR mutants more effectively than AZD9291. • ER121 exhibits anti-tumor activity against Herceptin resistant breast tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF